The international society for stem cell association (ISSCA) will participate in CONGRESO ESTÉTICA MUNDIAL 2022. Córdoba , Argentina, on October 01 and 02.
ISSCA has announced plans to participate as a sponsor in the Estetica Mundial congress. The organization has been promoting advances in regenerative medicine especially focused on the aesthetic field and will continue to explore new medical events like CONGRESO ESTÉTICA MUNDIAL to educate the Argentine medical community
As part of the program ISSCA faculty members will have a presentation and a practical workshop showing the latest application of regenerative medicine. ISSCA complete program will cover all the different topics related to regenerative medicine applications, guidelines and clinical protocols
About the Speakers
Dr. Maritza Novas
Dr. Maritza is a research and Development Director of Global Stem Cells Group in the USA. She is a pioneer in using cell therapies for therapeutic procedures. pain management. and aesthetic applications. She has an outstanding reputation for training over 2000 physicians globally on procedures and protocols for harvesting and isolating adipose-derived stem cells for autologous and allogeneic reim plantation. She will be covering the topic of Allogeneic Therapies and stromal cell exosomes.
Dr. Silvina Pastrana
She is a chapter director of ISSCA in Argentina and medical director of the stem cell center in Buenos Aires. Dr. Silvina is a Regentherapy s.a. medical surgeon. She has a master’s in aesthetic and anti-age medicine (AMA). an Ozonologist. and a master’s in pain management. Her topic in this congress will be Fundamentals of cellular therapies: mesenchymal cells.
Dr. Andrea Lapeire
She is an aesthetic medical practitioner with a postgraduate in obesity. biological medicine. homotoxicology. and environment. Her workshop demonstration will be on advanced regenerative medicine in alopecia and its basics.
Prof. Dr. Julio Ferreira
He is from Argentina is a professional cosmetic surgery and aesthetic medicine expert. He is a university professor of medicine and is the president of the South American Academy Of Aesthetic Surgery. He will cover regenerative therapies in rejuvenation and facial harmonization in the workshop.
Benito Novas is the managing director of the International Society for Stem Cell Application from the USA. He is the senior marketing consultant and founder of “Este’tica marketing INC”. as an Author. he has authored several books among them: su clinica este’tica. Lo que dicen sus pacientes” Marketing Digital en su Clinica Estetica” and “Marketing en Tiempos de Crisis” for more information on Novas you can check on www.benitonovas.com. In this congress. Benito Novas will be covering Digital Marketing in Cash-based practices.
ISSCA at Global Perspective
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
Exosomes are potent microvesicles released by adult mesenchymal stem cells. They have the ability to help restore cells in the body by improving cell to cell communication.
Exosomes are not cells, and they are smaller than cells. When compared to adult stem cells, exosomes have much more growth factors which give them a better clinical and aesthetic potential than stem cells.
It’s a cell-free cell therapy, this makes it safer compared to other cellular therapy, because there’s no risk of rejection in graft Vs host.
Unlike some other cellular therapies, exosomes do not produce host graft reactions, because they do not carry HLA genetic information and are not cells but extracts of the cells (released by cells).
Exosomes have a superior regenerative capacity, because they are obtained from newborn umbilical cord tissue mesenchymal cells, which means they have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body.
Exosomes improve the signaling between cells, thereby making them useful to revitalize, rejuvenate, restore, and cause anti-inflammatory effects in the body.
When compared to autologous adult stem cells, exosomes have much more healthy growth factors which gives them a better clinical and aesthetic potential than stem cells.
Exosomes are less complicated products to transport because the cells used in cellular therapy must be applied to the patient very quickly because they are live cells. In the laboratory, once they are thawed the doctors have limited time to apply them. However, with exosomes, they last longer, because as they are proteins they do not denature and can last for longer periods.
Exosomes is a superior product to autologous treatments because they do not require a surgical procedure, they come in a vial that can be injected directly, significantly reducing the risk and complications of a surgical procedure.
It is a superior product to autologous stem cell therapy because the patient’s cells have the same age and the same quality. For example, if a patient is a smoker and intoxicated, obviously the health of his cells is not the best. That is why the most indicated product is a donor product that is pure and free of toxins.
Mesenchymal cell-derived exosomes are preferably used in regenerative medicine. These cells are excellent regenerative cells due to their multipotent nature, therefore MSCs derived exosomes are superior to other exosomes products.
The Cellgenic lyophilized exosomes are derived from mesenchymal cells, which makes it superior to other exosome products, because mesenchymal cells have superior and excellent regenerative capacity.
This is why exosome therapy, especially Cellgenic lyophilized exosomes should be a doctor’s first choice.
Because of the complex nature of wound healing process, an injury on the skin can pose several challenges and are likely pose complications especially when they are acute. They can as well deteriorate from acute to chronic conditions which will require external intervention best understood by a specialist physician to get the area affected by the wound under normalcy.
The complexity of wound healing and research remains an ocean of knowledge that is continuously researched intensely to uncover depths of wound healing techniques and interventions. Hence, this report contains an introduction and details to the use of a new medical innovation called Gcells used primarily for the management of wounds in their different etiology.
In a case where the process of wound healing seemed difficult, Gcells proved great effects an attribute to their design and working protocol. Gcells are conditioned to work with an enriched suspension of progenitor cells that can efficiently aid tissue repair process. In this case report, two subjects were used as donors and acceptors of these micro-grafts.
The skin is an outer layer of the body, offering protection to the underlying layers. A wound breaks this layer and inhibits the various functions as well as expose or also break the underlying layer of tissues. Repair processes are inherent and part of homeostatic processes of the body to try to restore the skin back to its normalcy in structure and in function.
The basics for the skins repair mechanism is represented by a cloth and an inflammation where vessels dilate and monocytes activate leading to breakdown of necrotic tissues. This basic process can be inhibited or delayed by a number of varying factors that lead to deteriorative transformation of acute wounds to chronic forms. But if there is no alteration in the repair process, Mesenchymal cells kickstart proliferative process and begin to repair and restructure the affected tissues starting from the base. At the same time epithelial tissues begin to grow around the wound leading to a final step of the healing process. In this final stage, remodeling of the skin structure is primary and then maturation of a scar.
These processes are efficient best in certain conditions which if affected by factors such as cardiovascular ailment, diabetes, bacterial or any other genre of infection, can inhibit these processes.
Hence, it is necessary to understand in details these processes if there is going to be development or innovation for effective healing processes. Just as stated above, during the proliferative phase of wound healing, Mesenchymal cells are the key role players. Their structure includes a Mesenchymal stem cell (MSCs), multi potent in nature and offer supportive, therapeutic and trophic functions. They are also able to release viable trophic, anti-inflammatory cytokines and anti-apoptotic molecules that offer protection during the repair of wounded skin. MSCs also possess subpopulations that are stem-like nature commonly referred to as “side population” (SP) they have been found out to be enriched in over 1000-fold of progenitor cells and multipotent stem cells and as well exist in tissues and tumors. SP exists in a variety of organs and tissues, after an original discovery to be prominent in the bone marrow of a mouse. The organs with SP include the lung, liver, brain, mammary gland and in skeletal muscles.
In other discoveries, it was discovered that they probably may also be isolated in other tissues of the body. This discovery was in an in vitro and in vivo experiment when Dental Pulp Stem Cells (DPSCs) showed capability to differentiate into osteoblasts and built a woven bone by forming an Extracellular Matrix (ECM) secreted by the osteoblasts. The experiment drew results on the both the quality and quantity of the matrix formed by the DPSCs in the in vivo and in vitro experiment using Stem cells and accompanying biomaterials.
Thus proved that dental pulp holds potentialities of therapeutic strength and a rich source of progenitor/autologous cells that can be used to aid healing processes even applicable to regeneration of craniofacial bones.
This is the evidence that supports the working principle of Gcells innovation. Gcell successfully separates this side population with a size of 50 micron. At this cell population, they can form autologous micro-grafts and can either be used alone or alongside biomaterials prepared in a biocomplex ready for use when necessary.
In this case report, two subjects were used as donors and acceptors of these micro-grafts for enhanced healing of complex wounds through autologous micro-grafts using the Gcell.
Clinical case 1
The first case involves a woman at age 50 who does not have any diseases or disorders. She underwent a laparoscopic gastric bypass surgery and was doing well considering parameters of weightloss. Two years later she moved in for abdominoplasty bariatric. Later on, post complications showed preeminence of necrosis which was discovered after first medical examination were about 150 to 200cm2 at the end of the flaps. An initial necrosectomy showed an intense loss of tissue and we furthered to place the wound on VAC therapy and the patient in active participation of this therapy for one week then at home as an outpatient.
As an outpatient, there was improved and progressive wound cleansing while granulated tissues around the base area were cleared.
The VAC therapy after 2 months still left the margins of the wound deteriorated and surrounding areas not in axis with skin surface.
The Gcell protocol kickstarted after consent from the outpatient. We started by collecting a 3 cm2 skin sample from the patient for the purpose of obtaining the cell suspension needed to be injected to the granulation tissue (figure2).
We followed up with conventional wound treatment as in cleaning and replacement with sterile gauze dabbed with Vaseline. The wound area began to improve in both healing progress and general appearance. In two months, the undermined area disappeared as well as leveled to the axis of the skin surface. 2 months later, the wound reduced to a very little scar that is mild and smoothed compared to the initial condition. (figure 3).
A man who suffered liver cirrhosis, hiatal hernia and diabetic as well at the age of 78. Complex surgery was carried out and distal esophagectomy was performed. But hiatal hernia was not decreased into the abdomen, so he was booked up for corrective surgery. During the intervention the adhesions correlated to the previous abdominal operation and led to opening the colon for resection. Some postoperative complications by the appearance of entero-cutaneous fistulas, related to a colonic anastomosis dehiscence. A second intervention was inevitable hence a ileostomy protection and repackaging of colonic anastomosis. We closed the laparotomy using a biological prosthesis. But we met further complications from ascetic failure that needed intensive care hepatology.
Patient’s condition that included poor liver synthesis had its toll on the healing of the surgical wound. Just as the first case, necrotic tissues grew around the biological prosthesis. We conducted necrosectomy and the biological prosthesis was left half exposed. (Figure 5).
Further treatment of the wound using advanced medication helped cover the biological prosthesis with granulation tissue (figure 6).
Plastic surgeons conducted evaluations on the patient and the choice to do a rotation flap did not seem so appropriate. VAC therapy was used on the wound for about 15 days even though the device wasn’t efficient enough to maintain supposed suction in the presence of ileostomy. We proceeded to treat the patient further with Gcell protocol when wound dimension progressed to about 250cm2. The tissue granulation was of right margin near the ileostomy improved even though it appeared to be undermined. In summary, Gcell protocol has proved a great level of efficiency in healing and restoration of damaged tissues. This progress is certain to open way for employment in the clinical practice that involves the treatment and management of acute and chronic wounds and in any other field of medicine that will inevitably need an instrument to repair lesion on tissues.
Discussion and conclusion
We made it clear earlier in this document about the efficiency of Gcell protocol in its aid to wound healing especially for wounds that are likely to develop from acute to chronic conditions. The working principle for the Gcell used to obtain the viable progenitor cells used for the micrografts relies on one individual as both the donor and the acceptor. This will help to reduce complications that are related to implants or injected micrografts that are non-autologous. Gcell is flexible and can be used both during in operating rooms as well as in ambulatories. This innovation is vastly spreading and currently used in the fields of oral-maxillo-facial field proven by recent studies even though a greater area of its application widespread and acceptable in plastic surgery, dermatology and orthopedics.
Conclusion of this report brings to clarity in demonstration, an efficient, useful and low-risk innovation in the field of medicine, useful for areas in wound management and healing. However, the viability of the Gcell product still needs to be texted on subjects with different conditions and perspectives. But we assure that this device will prove to be a better therapeutic approach in the field of medicine in improving healing of complex wounds. This confidence lies in the excellent features and working principles of this device in obtaining cell suspension, flexibility, facility for procedure and more importantly, the cost. This will help reduce the use of exorbitantly prices devices for advanced medication. In summary, apart from introducing an efficient innovation in the medicine. Gcell has the potentialities to offer employment on clinical procedures that will help aid in the management of wounds no matter how the case may be.